This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Management of benign rolandic epilepsy of childhood

Authoring team

Sometimes this condition needs no treatment, especially if the seizures are simple partial in type, occur only at night and are infrequent.

Families should be counseled about relation to sleep deprivation, good sleep hygiene, and implications for sleepovers.

Neurodevelopmental screen is essential to detect possible speech and language problems, dyslexia or attentional impairment; further assessment by psychologist or speech therapist may be required.

Treatment practice varies - antiepileptic drugs are sometimes not prescribed when seizures are few, exclusively nocturnal and do not involve loss of consciousness. Where drug treatment is indicated, carbamazepine, sodium valproate or levetiracetam may be effective and the median period of active seizures is three years.

Rescue medication (buccal Midazolam) is indicated if generalized seizures have occurred.

Download free parental guide from https://childhoodepilepsy.org.

Contributor:

  • Professor Deb K Pal PhD MRCP
  • Professor of Paediatric Epilepsy
  • Honorary Consultant Paediatric Neurologist, Variety Club and Evelina Children's Hospitals

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.